Ethinylestradiol/drospirenone low-dose

Drug Profile

Ethinylestradiol/drospirenone low-dose

Alternative Names: BAY86-5300; BAY86-5300-YAZ-Flex; Dihydrospirorenone/ethinylestradiol low-dose; Drospirenone/ethinylestradiol low-dose; Ethinylestradiol-Drospirenone 24+4; Flexyess; SH T00186; SH-T-00186D; Yasmin® 20; Yasminelle; Yaz; Yaz 24+4; Yaz Extended Cycle; YAZ Extended Regimen; Yaz Flex; Yvidually

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals; Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals; Bayer HealthCare Pharmaceuticals Inc.
  • Class Alkylated estrogenic steroids; Androstenes; Norpregnatrienes; Oral contraceptives; Progesterone congeners; Small molecules
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Acne; Dysmenorrhoea; Pregnancy; Premenstrual dysphoric disorder; Premenstrual syndrome
  • Phase III Endometriosis

Most Recent Events

  • 15 Feb 2016 Bayer withdraws a phase III trial for Dysmenorrhoea in China, Germany and Russia (PO) (NCT02617537)
  • 03 Dec 2015 Bayer plans a phase III trial for Dysmenorrhoea in China, Germany and Russia (PO) (NCT02617537)
  • 01 Aug 2015 Bayer completes a phase-III trial for Dysmenorrhoea (flexible extended regimen versus 28-day regimen) in Japan (NCT01892904)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top